GleamWall
中文EN

RAJAF TFA Therapeutics, Inc.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1885680 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-0.6%
TTM net income YoY31.6%
TTM EPS YoY—
Revenue 3-yr CAGR185.9%
Net income 3-yr CAGR—

Margins

Gross margin61.1%
Operating margin-11.3%
Net margin-12.4%
FCF margin—
EBITDA margin-0.5%

Returns

ROE—
ROA-3.3%
ROIC (approx.)—
Asset turnover0.27x

Leverage & solvency

Liabilities / assets111.5%
Debt / equity—
Current ratio0.19x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.23x
Accruals ratio-2.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$1.25M$1.25M
Cost of revenue$484,607$347,004
Gross profit$760,741$906,480
Operating income-$141,128-$183,913
Pretax income-$154,822-$191,301
Income tax—$34,957
Net income-$154,822-$226,258
EBITDA-$5,885$223,352
EPS (basic)0.000.00
EPS (diluted)0.000.00
Weighted avg. shares (diluted)111.12M111.12M
Balance sheet
Cash & equivalents$3,199$37,284
Receivables—$305
Inventory$674,196—
Current assets$997,742$601,602
PP&E, net$3.63M$3.91M
Total assets$4.66M$4.62M
Current liabilities$5.19M$4.99M
Total liabilities$5.19M$5.00M
Shareholders' equity-$534,551-$375,543
Shares outstanding111.12M111.12M
Cash flow statement
Operating cash flow-$35,845$312,006
Capital expenditure—$349,237
Free cash flow—-$37,231
Investing cash flow—-$305,637
Depreciation & amortization$135,243$407,265

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.